Eli Lilly and Company (NYSE:LLY)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for LLY
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
-
scottrades: ...
$LLY Watch 1068.25
$FIVE Holding the 8 EMA.
Have a great day!
Scott
- Mikev200: $LLY watch next week
- scottrades: Good morning Team! Futures are up following a lower than expected CPI report. This new data gives the Fed a longer leash to cut rates at the next meeting in January and the market likes that. This could be just the clarity we need to rally into the e ...
- ThomasP: $LLY support at 21 DMA
- Mikev200: $LLY HOD.
- Dig44north: $LLY moving up above all ma’s, buying some back that I sold higher
- woodman: @Dig44north $LLY - Nice. I joined you. Thanks.
- Dig44north: @woodman $LLY they’re still rumoured to be looking at $VKTX
- woodman: @Dig44north $LLY $VKTX - Yeah those rumors have been around for a long time it seems. More like hopes, lol. I suspect $GPCR is being looked at too. Lots of potential targets in the obesity space.
- woodman: @Dig44north $LLY $VKTX - Keep an eye on $ALT (no position currently) in the space. Long $LLY (as of today thx to you) $VKTX $GPCR (stopped out yesterday but bought back) and $GUTS
- ThomasP: $LLY on 21 DMA(finally) on low vol
- Dig44north: $LLY riding the upper BB, beast mode, trimming some
- oldtimer: @StockMarketMentor $NVDA $LITE $CRDO $HOOD $BE $IREN $IBIT $WGS I am tracking your recent RSP list . . $CAT, $ISRG, $LLY, $NEE, $RTX, $XOM are the only ones above the 50 DMA . .
- woodman: $LLY unfazed.
- Bert953: @woodman $LLY I got shaken out months ago. Bummer!
- phgruver: @Bert953 $LLY $ABBV, $BMY, $CVS are also dong well....
- phgruver: @phgruver $LLY $ABBV $BMY $CVS oops, not $BMY, it's $PFE that's up 2.64% (as I type).
- Mikev200: $JNJ $LLY ATH
- Onthemark: Healthcare and Biotech inflows looking good $LLY, $MRK, $IBB, also like $ONDS, $GOOGL, $NRG, and lower volume $NVGS
- Bridgemate: $LLY I am likin' Lilly!
- woodman: @Bridgemate $LLY - Very nice, now at ath. $VKTX and $GPCR also with obesity meds in the works on the rise too.
- Bridgemate: @woodman $LLY $VKTX $GPCR both look good. I drank the koolaid on $VKTX, but it is looking good...
- dvargha: @Bridgemate $LLY I guess we need to see if it busts through $1,000 or hangs there for a while. It does look nice.
- woodman: $LLY on fire too. $VKTX $GPCR $PFE $NVO $MTSR $LLY
- champ: $LLY, sure looks like it wants to make a New 52-week high.
- scottrades: $LLY Can't stop won't stop.
- scottrades: $LLY Volume. They are being exempt from Tariffs for 3 years.
- woodman: @scottrades $LLY - obesity drug price control deal announced. Happy to see it. Just don't call it socialism. https://www.cnbc.com/2025/11/06/trump-eli-lilly-novo-nordisk-deal-obesity-drug-prices.html
- DavidK: @woodman $LLY $NVO - based on earnings projections for 2026 on ETrade this stock is trading at a 2 PE . Can’t be correct can it . If so we need to pile in
- woodman: @DavidK $LLY $NVO - NVO has been a series of "h" patterns (continuations of downtrend) seen well on the weekly. Is this finally going to be a double bottom ready to bounce and get moving up in earnest instead of continuation of "h" patterns down? I don't know, but fugly thus far.
- woodman: @woodman $LLY $NVO - Also, LLY's drug is superior to NVO's, fwiw.
- DavidK: @woodman $LLY $NVO 👍🍺
- joelsg1: $LLY $NVO $GPCR All flying on rumored WH deal on GLP-1 drug prices.
- woodman: @joelsg1 $LLY $NVO $GPCR - supposedly, under the deal, they would offer the lowest dose of their obesity meds at $149/month. In return, the products would gain Medicare coverage which would provide for a new set of reimbursement.
- Vcondry: $lly looks pretty on such a ugly day
- ReneeH: @Vcondry $lly agree, lot's to like in this chart imo. also $PODD
- Vcondry: @ReneeH $lly $PODD great spot on $PODD thanks!
- shoredriver: @Vcondry $lly $PODD ...earnings bmo Thursday.....
- Vcondry: @shoredriver $lly $PODD yeah i'll wait and watch and hopefully ride some post earnings momentum up.
- scottrades: My notes: $SPY Filling the Gaps $QQQ Filling the Gaps $IWM Under the 50 Day $SMH Under the 8 EMA $XHB Sitting on the 200 Day $GLD Not ready $IBIT Under the 200 Day $XLI Clinging on to the 50 Day $XLF Good RS $IBB Not terrible $XLV Good RS $AAPL Holding the 8 EMA $BNS In an uptrend $JPM Watch 312.90 $GS Watch 806 $LDOS Up on Earnings $UBER Upside reversal $TSLA on the 21 EMA $LLY Good RS $CBOE Near the highs $DINO Tight near the 50 Day $INCY Good RS but extended $CAH Good Momentum, Watch 197.70 $AER Mentioned by Dan $WGS Flag
- scottrades: My notes $SPY Still in trend $QQQ Still in trend $IWM Still above the 50 Day $SMH Still in trend. $GLD Want to see it continue to firm up $GDX Watch it near the 50 Day $XLK Still in trend $IBIT Holding above the 200 Day $NVDA Still above the MAs $AAPL Up AH $AMZN Up AH $NFLX Stock Split $TSLA Around the 21 EMA $PLTR Watch 200 $MDB Good RS $CSCO Good RS $SNOW Watch 273.30 $LLY Watch the slope line
- scottrades: Watch $LLY for a move through 864
- Vcondry: $LLY looks pretty good if it can hold $830 here (whats Lilly gotta do with China?)
- traderbren: $LLY - pushing for a gap close at 802.50
- mopick: $LLY, at the 50d. Wary of this one, though.
- ReneeH: @mopick $LLY me too, been watching...actually looks a little bearish wedgey to me.
- camaro69: $LLY may be worth watching for a phase 3 move in the near future.
- ReneeH: @camaro69 $LLY been watching too...oddly potential for bearish wedge or maybe I'm seeing it more fearfully?
- camaro69: @ReneeH $LLY you're seeing it right! time will tell.
- marklesparkle: @ReneeH $LLY Plus Mr. 50d is sitting there along the trend line like @camaro says time will tell on this baby. Good eye good eye
- DavidG: @woodman $LLY $VKTX I like your comment that the oral drugs will be used for maintenance once weight loss is achieved with the parenteral forms. Also no physician who uses these has the high adverse reactions cited in the studies because we presccribe these at lower doses based on tolerance not on some artificial timetable dictated by study design.
- Henry: $LLY Up on news it's oral fat pill is moving forward
- woodman: @Henry $LLY - 10.5% weight loss in 72 weeks - a year and a half basically. Eh. $VKTX had 12.5% weight loss for its oral in 13 weeks. Subcutaneous remains the version that provides serious weight loss, though. Moreover, at the end of the day, I think it will come down to which of the drugs patients can tolerate and stay on. If you're throwing up, or can't have a BM, or have diharrea, and these can't be managed significantly, you're not going to stay on the drug for long.
- traderbren: $LLY - ugly chart, but pushing for a gap close on the upside to 740
- traderbren: $LLY - may be pushing for a gap fill up to 740
- camaro69: $LLY HOD
-
woodman: ...
All that said, the stock has been squashed back down to pre-run-up levels at the June low where it is now desperately battling to hold on. I could see it go even lower from here - today or in the following days. I make no predictions from here, thou ... - ReneeH: @woodman $VKTX $NVO $LLY it's a love hate here, when they move they move....both directions unfortunately. I feel ya.
- woodman: @ReneeH $VKTX $NVO $LLY - Trading vs investing, too. You can trade anything generally (though see below for biotech, specifically), but investing is a different thing. I think investing in small/mid cap biotech, particularly with no approved drugs, i ...
- ReneeH: @woodman $VKTX $NVO $LLY 100% agree, thank you. I'm much more of a trader vs investor. With biotech, I've had a few great hits and a lot of disappointment. Very tricky to time just right.
-
woodman: ...
Finally, as the review suggests, comparing VKTX's 12% weight loss at just 13 weeks vs. $LLY's oral version which achieved 11% at 72 weeks and $NVO's oral which achieved 14% at 64 weeks is - on its face - an unfair comparison. But they were Phase 3 d ... - joelsg1: @woodman $VKTX $LLY $NVO $LLY is preparing to flood the zone with their pill even before approval. I think it's a mistake to discount the no-needle convenience of the daily pill, but once massive supply is available, it's pretty much Game Over for the competitors, unless there's a huge difference in tolerability. And even on that last point, millions of people continue to take statins because they see immediate improvement in their cholesterol numbers, despite the fact that for many their feet, ankles, leg muscles hurt.
- woodman: @joelsg1 $VKTX $LLY $NVO - Funny thing is, I know many on the injectibles, and not one of them complains about it. It's such a nothing burger. At least not from a pain standpoint. But yes swallowing a pill is more convenient than dealing with syringes and vials or even autoinjectors.
- Bs7518: @woodman $VKTX $LLY $NVO Thanks for sharing the article I take the shot once a week and your right the pain is nothing so the pill is import to me but as an investor it is.
- mopick: $LLY, working it's way up to fill the gap, long
- woodman: $LLY https://finance.yahoo.com/news/eli-lilly-taps-high-grade-132106942.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAHqDnGToIGKiUcNfY-BtXgihmm7J6SAUNNT4j-yHm-9v-g5qDF6Uddo0Hyk2Tb6XYFWEnS62ElBo_5uEdGbz0S4ZtnddRzL33_MtNdgwU2TC5l63vfcWtkgVfw94rTnX-tcFcD8Daf-b0GWkcI8UkyTduyjqrpjLEwIWISe2y2NK
- camaro69: $LLY nearing HOD
-
woodman: ...
$VKTX - running up into oral obesity med data (expected 2H25 according to the company, but speculation is this or next month.) If the data are good, not just weight loss but, as expected, best in class tolerance/safety, it will be the best oral cand ... - traderbren: $LLY - pushing into upside gap. Not sure how much it can chew through as there's a ton of overhead supply.
- Vcondry: @traderbren $LLY i just got my $680 MS alert ... but im with you lots of overhead.
- DAN: @Vcondry $LLY Gap filling time!
- Vcondry: @DAN $LLY worth playing anything here?
- traderbren: $LLY - looks like they are trying to prop up the stock but it looks like there is more downside...in time. Eli Lilly & Co Insider Bought Shares Worth $1,052,263, According to a Recent SEC Filing
- woodman: $VKTX up again as the breakout/run into coming Phase 2 data (for the oral version of its obesity med) continues. I'm significantly long this one starting from ~$30. I suspect from past practice that the company will announce a date for it to provide ...
- ReneeH: @woodman $VKTX $LLY fantastic catch last week! watching for a long time, missed it but like it mucho. Thank you.
- woodman: @ReneeH $VKTX $LLY - Thanks. I started building in early-mid July, so it's been a bit of a wait and see.
- ReneeH: @woodman $VKTX $LLY tough spot here, but tempting. Data has been positive to date, higher quality than $HIMS, could do something "could" big
- woodman: @ReneeH $VKTX $LLY $HIMS - And bio, in general, is treacherous.
- billyzeke: $LLY's loss is $NVo's gain....there's a weight joke in there somewhere. I have no position in either.
- traderbren: @billyzeke $LLY $NVo - yeah, there probably is. Interesting to note that $NVO is up on the day while $LLY is tanking on the news. $NVO's pill performs better than $LLY.
- traderbren: $LLY - gap at 672.62
- woodman: $VKTX up on less than impressive $LLY oral weight loss med 72 week data. That said, I don't think this is what will cause a jail break for VKTX. The market is waiting for VKTX to report its own oral data, which folks seem to think will be reported this or next month. I am holding some VKTX for the data.
- wijimmy: $LLY getting slapped back to 2023 prices .. OVER REACTION… due to obesity pill results …. People on it only lost 12% of their body weight in one year of treatment…. which fell short of expectations, which WERE 15% of body weight. Worth watching IMHO
- Vcondry: @wijimmy $LLY 100% agree but no point in trying to be a hero...watching only for now.
- wijimmy: @Vcondry $LLY …. Ditto watching it in coming days like the.$AMZN and $SMCI trades
- bigreek42: $lly bouncing
- Geewhiz: $VKTX 11% pop on $LLY lack of good numbers on their oral obesity trials??
- woodman:
- woodman: @Geewhiz $VKTX $LLY - Correct. I've been holding shares for VKTX's coming oral data. I think it will come this or next month. I wouldn't mind seeing a run starting now on this lackluster LLY data.
- AndStars: @woodman @Bert953 The GLP-1 and GIP agonists are truly game changers. Not merely cosmetic. Truly improve the health directly by weight loss, but also in so many ways beyond mere weight loss. Cardiovascular disease. Diabetes. Depression. Anxiety. Kidney disease. OSA (obstructive sleep apnea). Peripheral neuropathy. To name a few. Besides increasing life span and quality of life, these drugs will be shown to save huge amounts on healthcare costs. Even at their high prices (which with time will come down) the cost vs. benefit is a no brainer. One reason why $LLY and $NVO can justify. Time for the health insurance industry ($UNH, et al) to get on board and cover this. It will reduce their costs by preventing expenditures on the above preventable disease states.
- woodman: @AndStars $LLY $NVO $UNH - I totally agree.
- joelsg1: $AMGN After $40 rise from triple bottom over past year, 3 day handle stopped at 20d intraday and reversed. Reports Monday Phase 2 results for weight loss drug Maritide at American Diabetes Assn., less frequent dosing and side effects compared with $LLY and others, up to bimonthly. Legacy long from way below, looking for bounce and collecting 3.2% divi.
- Henry: $VERV Gene editing, being bought by $LLY, trading above the buy out price of 10.50
- Dig44north: $LLY climbing the upper BB to take out the 200dma, macd curling up, on a nice run
- Dig44north: $LLY moving on Swedish drug deal, trying to regain the 50dma, full position
- makebackthemill: $LLY I am long this stock in my retirement portfolio. -- Forgetting the chart. It seems to me, a company that has invented the pill that will help people lose weight. (Pretty sure they passed their third trial) should be one of the greatest stocks of all time. Similar to the birth control company that invented the pill. Only LLY's pill can be USED by TWICE as many people. I just wanted to sound off about this because it drives me crazy that this stock isn't at least triple. Others are working on the pill, but are way behind. Any thoughts are welcome.
- woodman: @DavidK $SEPN $NVO - The weight-loss drug makers are looking for new molecules. $NVO is losing the GLP-1 battle to $LLY's Zepbound (current best in class). Orals are coming, as are new molecules. It's an ever-evolving area and new assets are needed. Companies mostly need to find them outside their own walls. $2 billion is inexpensive for these assets, if remotely promising. Many drug MFR CEOS want deals under $5 billion; under $3 billion even better.
- DavidK: @woodman $SEPN $NVO $LLY moving up into the close as I expected.
- woodman: @DavidK $LLY - It won't be every drug. Likely top Medicare drugs to be targeted. But no one - not even Pharma company management - knows right now.
- woodman: @DavidK $LLY - Moreover, if the plan is for the Administation to directly and unilaterally control drug prices by EO - also known as socialism, by the way - the courts will most likely strike it down as a clear separation of powers problem. This is the realm of Congress, not the President by EO. So, I'd say everyone should just cool their engines and wait to see what actually emerges from this on-going process. I can tell you, after speaking to a pricing guy I know in the Pharma industry, no one knows what this will end up being.
| Stock Price | $906.70 |
| Change | -1.18% |
| Volume | 4,815,710 |
Eli Lilly and Company is a drug manufacturing company. It discovers, develops, manufactures, and sells products in two business segments: human pharmaceutical products and animal health products.
Request Video of LLYAlready a member? Sign in here.
Past Month
Leading Peers
-
$45.33 167.44%
-
$6.00 31.93%
-
$7.05 18.49%
Past Month
Lagging Peers
-
$9.29 -47.33%
-
$33.18 -42.63%
-
$19.54 -37.85%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!